Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
Healthcare
$26.20 +0.93%
+$0.14 today
- Market cap
- $3.37B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
52W Low $4.80High $18.61
Volume 1.76M
Average 1.21M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$123.34M
FY 2025 · Annual
Investing Cash Flow
$14.04M
FY 2025 · Annual
-81.4% YoYFinancing Cash Flow
$257.03M
FY 2025 · Annual
+73758.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.14M | 21.71M | 37.16M | 33.04M | 27.65M |
| Change in Working Capital | 4.6M | (1.64M) | (65.66M) | (45.83M) | (1.08M) |
| Accounts Receivables | (144K) | (15.31M) | (24.74M) | 39.6M | 383K |
| Inventory | 0 | (9.77M) | (73.13M) | (9.25M) | 0 |
| Accounts Payables | 670K | 1.85M | 15.88M | (19.1M) | 580K |
| Other Working Capital | 4.07M | 21.58M | 16.33M | (57.08M) | (2.05M) |
| Other Non-Cash Items | 5.35M | (2.06M) | (9.94M) | 145.99M | (5.7M) |
| Operating Cash Flow | (74.8M) | (179.87M) | 11.92M | (167.65M) | (123.34M) |
| Capital Expenditures | (353K) | (2.53M) | (1.24M) | (157K) | (138K) |
| Acquisitions (Net) | 0 | 236.46M | 0 | 0 | 0 |
| Purchases of Investments | (49.05M) | (415.87M) | (300.83M) | (231.99M) | (231.82M) |
| Sales of Investments | 3M | 179.41M | 394.12M | 344M | 246M |
| Other Investing Activities | 0 | (236.46M) | 0 | (36.2M) | 0 |
| Investing Cash Flow | (46.41M) | (238.99M) | 92.05M | 75.65M | 14.04M |
| Debt Repayment | 25.9M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 432.45M | 6.86M | 2.13M | 260.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.39M) | (658K) | (3.32M) | (1.78M) | (3.36M) |
| Financing Cash Flow | 158.51M | 431.79M | 3.54M | 348K | 257.03M |
| Effect of Forex Changes | 13K | (65K) | 160K | (438K) | 1.07M |
| Net Change in Cash | 37.31M | 12.87M | 107.68M | (92.08M) | 148.8M |
| Free Cash Flow | (75.15M) | (182.4M) | 10.68M | (167.8M) | (123.48M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$144.7M
+ D&A$525.0K
+ Stock-Based Comp$27.6M
+ Deferred Tax$0
- Working Capital-$1.1M
- Other Non-Cash-$5.7M
= Operating Cash Flow-$123.3M
- Capex-$138.0K
= Free Cash Flow-$123.5M
Analysis
FY2025 free cash flow is -$123.5M. FCF conversion is 85.3% of net income. Operating cash flow was -$123.3M, with capex of -$138.0K. The largest bridge item is Stock-Based Comp at $27.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does AMLX generate free cash flow?
Amylyx Pharmaceuticals, Inc. (AMLX) generated -$123.48M of free cash flow in fiscal 2025.
How much operating cash flow does AMLX produce?
Operating cash flow was -$123.34M, before capital expenditures of $138,000.00.
Continue the stock analysis
Jump to another research area for this company.